


PHARMACEUTICAL 2017

NeuroBo Pharmaceuticals Inc. Rank 180 of 313







PHARMACEUTICAL 2017

NeuroBo Pharmaceuticals Inc. Rank 180 of 313

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 314% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -253%, being 164% points above the market average of -417%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 24,746 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 4,121 |
| Liabilities, Non-Current | 1.0 |
| Other Assets | 8.0 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 110 |
| Property and Equipment | 0 |
| Research and Development | 8,740 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 5,956 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 24,754 |
| Liabilities | 4,122 |
| Expenses | 14,696 |
| Stockholders Equity | 20,632 |
| Net Income | -14,586 |
| Comprehensive Net Income | -14,586 |
| Economic Capital Ratio | -253% |

